Amount Raised
$59.5 Million
Round Type
Series A
BerkeleyBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today it has extended its Series A financing round with an additional close of $25.5 million, bringing the total Series A amount raised to $59.5 million. The extension was co-led by existing investors Boehringer Ingelheim Venture Fund and Illumina Ventures, with GKCC LLC as a new investor joining the round with Actym's other current shareholders, Panacea Ventures and JLo Ventures.
Quick answer
Actym Therapeutics raised $59.5 Million in a Series A round, dated October 18, 2023. Investors: Gkcc, Llc, J Lo Ventures, Panacea Ventures, Illumina Ventures and Boehringer Ingelheim Venture Fund. Actym Therapeutics is based in Berkeley, California, United States.
- How much did Actym Therapeutics raise?
- Actym Therapeutics raised $59.5 Million in a Series A round on October 18, 2023.
- Who invested in Actym Therapeutics?
- Gkcc, Llc, J Lo Ventures, Panacea Ventures, Illumina Ventures and Boehringer Ingelheim Venture Fund are named as investors in this round.
- What does Actym Therapeutics do?
- Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies.
- Where is Actym Therapeutics based and how big is it?
- Actym Therapeutics is based in Berkeley, California, United States.
- Who are the decision-makers at Actym Therapeutics?
- Fundz holds 1 contact at Actym Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Actym Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- On Target Laboratories raised $30M (Funding Round) on November 16, 2023.
- MAIA Biotechnology raised $4.9M (Seed) on November 15, 2023.
- EyeBio raised an undisclosed amount (Series A) on November 14, 2023.
- MBrace Therapeutics raised $85M (Series B) on November 14, 2023.
- Ascidian Therapeutics raised $40M (Series A) on November 8, 2023.
- Lipella Pharmaceuticals raised $3.1M (Seed) on October 23, 2023.
Who to call at Actym Therapeutics, and when
A new round usually means Actym Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Actym Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Actym Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Actym Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Actym Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansActym Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.